Suchergebnisse - (Subject:"coronavirus")

PubPharm (899)

1

Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections

enthalten in: Viruses | 2024

von Hurwitz, S. | De, R. | LeCher, J. | +12

2

Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity

enthalten in: Bioorganic & medicinal chemistry | 2024

von Carney, D. | Leffler, A. | Bell, J. | +17

3

Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors

enthalten in: Antiviral research | 2024

von Khatua, K. | Alugubelli, Y. | Yang, K. | +17

4

Sensitive detection of SARS-CoV-2 main protease 3CLpro with an engineered ribonuclease zymogen

enthalten in: Protein science : a publication of the Protein Society | 2024

von Wralstad, E. | Raines, R.

5

In-silico guided design, screening, and molecular dynamic simulation studies for the identification of potential SARS-CoV-2 main protease inhibitors for the targeted treatment of COVID-19

enthalten in: Journal of biomolecular structure & dynamics | 2024

von Gutti, G. | He, Y. | Coldren, W. | +5

6

Venomous gland transcriptome and venom proteomic analysis of the scorpion Androctonus amoreuxi reveal new peptides with anti-SARS-CoV-2 activity

enthalten in: Peptides | 2024

von Ghazal, A. | Clarke, D. | Abdel-Rahman, M. | +13

7

Public Health Impact of Paxlovid as Treatment for COVID-19, United States

enthalten in: Emerging infectious diseases | 2024

von Bai, Y. | Du, Z. | Wang, L. | +7

UpdateOf: medRxiv. 2023 Sep 07;:. - PMID 37732213

8

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong

enthalten in: Emerging infectious diseases | 2024

von Cheung, Y. | Lau, E. | Yin, G. | +3

9

Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak : A strategy to tackle challenges of persistent virus infection

enthalten in: European journal of medicinal chemistry | 2024

von Tian, L. | Qiang, T. | Yang, X. | +9

10

Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19

enthalten in: Med (New York, N.Y.) | 2024

von Mao, L. | Shaabani, N. | Zhang, X. | +38

ErratumIn: Med. 2024 Feb 9;5(2):169-171. - PMID 38340710

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[90]